Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.47 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13876231 | 0.90 | DDR1 (0.52) | EPHX2DDR1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL13876213 | 0.80 | EPHX2 (0.56) | EPHX2MAPK14RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL13876232 | 0.79 | DDR1 (0.63) | EPHX2DDR1MAPK14MAPTNR1H4 | |
| SCHEMBL13876237 | 0.75 | HPGDS (0.51) | EPHX2DDR1DGAT2 | |
| SCHEMBL13876171 | 0.74 | TSHR (0.61) | EPHX2MAPK14CYP3A4LMNANR1H4 | |
| SCHEMBL13876241 | 0.72 | EPHX2 (0.49) | EPHX2DDR1MAPK14DGAT2NR1H4 | |
| SCHEMBL13876187 | 0.72 | EPHX2 (0.58) | EPHX2MAPK14 | |
| SCHEMBL13876233 | 0.72 | ALDH1A1 (0.51) | EPHX2DDR1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL13876240 | 0.72 | EPHX2 (0.51) | EPHX2DDR1NR1H4 | |
| SCHEMBL13876234 | 0.71 | SCN10A (0.52) | EPHX2DDR1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| WO-2007098352-A2 | SUBSTITUTED PYRIDINEAMIDE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885DDR1 3354/4885MAPK14 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.